CRISPR Therapeutics AG financial data

Symbol
CRSP on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
Baarerstrasse 14, Zug, Switzerland
State of incorporation
Switzerland
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.62K % +11.9%
Debt-to-equity 19.2 % -2.39%
Return On Equity -11.6 % +57.1%
Return On Assets -9.7 % +57%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 84.9M shares +7.58%
Common Stock, Shares, Outstanding 84.8M shares +7.58%
Entity Public Float 4.1B USD -4.65%
Common Stock, Value, Issued 2.66M USD +8.4%
Weighted Average Number of Shares Outstanding, Basic 81.8M shares +3.96%
Weighted Average Number of Shares Outstanding, Diluted 81.8M shares +3.96%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 272M USD +171%
Research and Development Expense 364M USD -18%
General and Administrative Expense 71.8M USD -25.9%
Operating Income (Loss) -299M USD +46.8%
Nonoperating Income (Expense) 83.8M USD +139%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -215M USD +59.2%
Income Tax Expense (Benefit) 2.29M USD -45.2%
Net Income (Loss) Attributable to Parent -217M USD +58.6%
Earnings Per Share, Basic -2.7 USD/shares +59.8%
Earnings Per Share, Diluted -2.7 USD/shares +59.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 707M USD +105%
Marketable Securities, Current 1.4B USD -8.97%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Assets, Current 2.12B USD +11.1%
Property, Plant and Equipment, Net 147M USD -9.21%
Operating Lease, Right-of-Use Asset 151M USD -1.36%
Other Assets, Noncurrent 9.37M USD +239%
Assets 2.44B USD +8.67%
Accounts Payable, Current 16.5M USD -63.5%
Employee-related Liabilities, Current 7.48M USD -10.4%
Accrued Liabilities, Current 76.4M USD -10.7%
Contract with Customer, Liability, Current 4.07M USD
Liabilities, Current 119M USD -18.9%
Contract with Customer, Liability, Noncurrent 13.5M USD +9.88%
Operating Lease, Liability, Noncurrent 219M USD -2.5%
Other Liabilities, Noncurrent 3.62M USD -37.7%
Liabilities 355M USD -8.83%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.55M USD +83.5%
Retained Earnings (Accumulated Deficit) -1.12B USD -24.1%
Stockholders' Equity Attributable to Parent 2.08B USD +12.3%
Liabilities and Equity 2.44B USD +8.67%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 110M USD +1147%
Net Cash Provided by (Used in) Financing Activities 306M USD +5561%
Net Cash Provided by (Used in) Investing Activities -97.8M USD -183%
Common Stock, Shares Authorized 130M shares -13.2%
Common Stock, Shares, Issued 85M shares +7.55%
Common Stock, Par or Stated Value Per Share 0.03 CHF/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 318M USD +141%
Deferred Tax Assets, Valuation Allowance 228M USD +14.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.12 pure 0%
Deferred Tax Assets, Gross 308M USD +9.43%
Operating Lease, Liability 239M USD -2.21%
Depreciation 19.6M USD -15.2%
Payments to Acquire Property, Plant, and Equipment 721K USD -76.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -209M USD +59.5%
Lessee, Operating Lease, Liability, to be Paid 323M USD -5.17%
Property, Plant and Equipment, Gross 206M USD +2.21%
Operating Lease, Liability, Current 16M USD +1.75%
Lessee, Operating Lease, Liability, to be Paid, Year Two 28.8M USD +8.67%
Lessee, Operating Lease, Liability, to be Paid, Year One 28.7M USD -1.94%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Deferred Income Tax Expense (Benefit) -424K USD +58%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 84M USD -12.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 29.4M USD +12%
Deferred Tax Assets, Operating Loss Carryforwards 133M USD +12.6%
Deferred Federal Income Tax Expense (Benefit) -424K USD +58%
Current Income Tax Expense (Benefit) 3.31M USD +384%
Unrecognized Tax Benefits 44.1M USD +27.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 28.7M USD +7.19%
Operating Lease, Payments 27.3M USD +60.6%
Current State and Local Tax Expense (Benefit) 994K USD +312%
Current Federal Tax Expense (Benefit) 2.32M USD +422%
Depreciation, Depletion and Amortization 4.83M USD -4.32%
Deferred Tax Assets, Net of Valuation Allowance 80.2M USD -3.38%
Share-based Payment Arrangement, Expense 79.6M USD -14.5%